Company Theracryf Plc

Equities

EVG

GB00BSVYN304

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Theracryf Plc

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - London S.E. Other stock markets 11:35:01 2024-05-17 am EDT			5-day change	1st Jan Change
0.75 ^GBX	0.00%		0.00%	-53.12%

Apr. 26	Evgen Pharma plc will Change its Ticker to TCF from EVG	CI
Apr. 26	Evgen Pharma plc will Change its Name to TheraCryf plc	CI

Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage therapeutics company. The Company is engaged in developing a new generation of therapeutics in oncology and behavioral brain disorders. Its pipeline and lead compound SFX-01 is derived from its proprietary Sulforadex technology. Its Sulforadex technology synthesizes sulforaphane into an active, stable, and solid form pharmaceutical ingredient, unlocking its medical and commercial potential. SFX-01 is a complex of sulforaphane and alpha-cyclodextrin formulated as a stable tablet. The Company has a candidate orexin 1 antagonist at late preclinical stage targeting addictive behaviors. It also has a candidate molecule DAT inhibitor at late preclinical stage targeting fatigue and narcolepsy.

Number of employees: 10

GBP in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	0	nan %	0	100.0 %	-

GBP in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
Huw Jones CEO	Chief Executive Officer	62	-
Toni Haenninen DFI	Director of Finance/CFO	-	23-09-04
Glen Clack CTO	Chief Tech/Sci/R&D Officer	-	21-04-30
Helen Kuhlman PRN	Corporate Officer/Principal	-	21-03-31

Members of the board	Title	Age	Since
Huw Jones CEO	Chief Executive Officer	62	-
Susan Foden CHM	Chairman	71	14-11-20
Alan Barge BRD	Director/Board Member	-	15-10-20
Toni Haenninen DFI	Director of Finance/CFO	-	23-09-04

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	427,346,895	272,708,358 ( 63.81 %)	0	63.81 %

Name	Equities	%	Valuation
James Robert Kight 7.745 %	33,100,000	7.745 %	310 809 p
Rathbones Investment Management Ltd. 6.035 %	25,789,246	6.035 %	242 161 p
Octopus Investments Ltd. 5.119 %	21,875,000	5.119 %	205 406 p
Vulpes Investment Management Pte Ltd. 4.810 %	20,554,191	4.810 %	193 004 p
First Equity Ltd. 4.680 %	20,000,000	4.680 %	187 800 p
SPARK Venture Management Ltd. 3.788 %	16,186,446	3.788 %	151 991 p
Seneca Partners 3.494 %	14,932,071	3.494 %	140 212 p
AXA Investment Managers UK Ltd. 3.136 %	13,399,724	3.136 %	125 823 p
Chelverton Asset Management Ltd. 2.925 %	12,500,000	2.925 %	117 375 p
RAB Capital Ltd. (Investment Management) 2.048 %	8,750,000	2.048 %	82 163 p

Evgen Pharma Plc

Block 24, Alderley Park Suite 24G13

SK10 4TG, Nether Alderley

+44 1625 315 090

http://www.evgen.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
THERACRYF PLC	-53.12%	4.07M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs